Europe PMC How Europe PMC can help you find associations between genes and diseases In this day and age of information deluge, how do you stay up-to-date with the latest advances in the field of drug discovery? The chances are you read publications, preprints, patents, or other
release notes The latest release of the Open Targets Platform is out! We have just released the latest version of the Open Targets Platform, release 18.04. These are some of the highlights. Our favourite stats Targets Diseases Evidence Associations 21,016 9,700 6,
Open Targets Touring with Takeda You may have seen the news on Takeda joining Open Targets from December last year. Takeda (native name 武田薬品工業株式会社) was founded in Doshomachi, Osaka, Japan in 1781. It started as a small shop
Open Targets Open Targets Platform: we have a new release We have just released the latest version of the Open Targets Platform, release 18.02. These are some of the highlights. Our favourite stats targets diseases evidence associations 20,974 9,728 5,
Open Targets How to predict the success of drug development The journey into drug discovery is not for the faint-hearted. From the very start when we develop an idea, or therapeutic hypothesis, to the very end, when the drug is ready to reach
Open Targets How CRISPR will guide the way to better cancer therapies With World Cancer Day just around the corner, I find that this is the perfect time to pause and remind myself why I do what I do. For many cancers we don’t
Open Targets Translation, Translation, Translation Over the last 14 days, we have had two scientific meetings taking place right here on the Wellcome Genome Campus, the Translational Bioinformatics conference and the Translational Target Validation symposium. What did they
targetvalidation.org Direct versus indirect evidence: should you care? The latest release of our Open Targets Platform contains 5.1 million pieces of evidence for target-disease associations. Where does this evidence come from? How do we integrate the different evidence types? Our
Open Targets Open Targets - First Impressions I recently joined the Open Targets Consortium as Operations Director. This moved me from almost the very end of the R&D pipeline where I had been working on processes for small
targetvalidation.org What do we have in store for you in the run up to Christmas? The latest release of our Open Targets Platform is out. We have plenty of new web features and new data to help your journey into drug discovery. These are our latest stats: 31,
targetvalidation.org An approach to visualising pathway evidence The starting point in drug discovery is often a specific target or disease. But what if instead you have a specific pathway to start with? As part of an Open Targets research project
targetvalidation.org Did you see the latest version of Open Targets Platform? That's right. The Open Targets Platform v1.2 is out! In this release, we have new web displays and plenty of extra data to assist you in drug discovery and validation: 30,591
Open Targets Outreach in Open Targets: supercharge your target identification skills What is it? Outreach, you may have heard the word before. But what is it, really? According to the Cambridge Dictionary, outreach is an effort to bring services or information to people where
